Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The net proceeds will be used to advance company's portfolio of novel, next-generation, small molecule therapies for chronic immunological and inflammatory disorders, towards clinical development.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?